DalsnaFinance Account

Baxter International $BAX

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Illinois

Create a scorecard

$24.51

-0.48 (-1.92%)

As of Oct 21, 2026, 4:39 AM EDT · cached

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 28, 2026, the first target we tracked for BAX.

Key facts

52-week range (closes): $15.80 – $28.35 Lowest close Mar 30, 2026, highest Aug 4, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings: Oct 29, 2026, before the open · EPS forecast $0.51 Nasdaq earnings calendar, as of Oct 21, 2026
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Sep 30, 1972 · All S&P 500 changes
Analyst coverage: 1 open price target from 1 firm: Stifel Approved targets tracked here; see the analyst section below

Baxter International (BAX) is trading down at $24.51 (-1.92%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on BAX

One firm's current price target on Baxter International: $24 — 2% below the current $24.5. Each is tracked to its date and scored the same way a member's call is.

Stifel $24.4 → $24 by Jul 2027 Hold Jul 28, 2026 via Investing.com · Stifel's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Baxter International revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Baxter International annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$10.2B	$10.6B	$11.1B	$11.4B	$11.7B	$12.1B	$10.1B	$10.4B	$10.6B	$11.2B
Growth (year over year)	+2.0%	+4.1%	+4.9%	+2.4%	+2.7%	+4.1%	−17.2%	+3.0%	+2.7%	+5.7%
Gross profit	$4.12B	$4.47B	$4.76B	$4.76B	$4.59B	$4.72B	$3.55B	$4.15B	$3.98B	$3.38B
Gross margin	40.5%	42.3%	42.9%	41.9%	39.3%	38.9%	35.3%	40.1%	37.5%	30.1%
Operating income	$745.0M	$1.29B	$1.58B	$1.77B	$1.62B	$1.35B	−$2.85B	$707.0M	$14.0M	−$308.0M
Operating margin	7.3%	12.2%	14.3%	15.6%	13.8%	11.1%	−28.3%	6.8%	0.1%	−2.7%
Net income	$4.96B	$602.0M	$1.55B	$1.00B	$1.10B	$1.28B	−$2.43B	$2.66B	−$649.0M	−$957.0M
Net margin	48.9%	5.7%	13.9%	8.8%	9.4%	10.6%	−24.2%	25.6%	−6.1%	−8.5%
EPS (diluted)	$9.01	$1.08	$2.83	$1.93	$2.13	$2.53	−$4.83	$5.23	−$1.27	−$1.87
Balance sheet
Cash and equivalents	$2.80B	$3.39B	$1.84B	$3.33B	$3.73B	$2.95B	$1.62B	$3.08B	$1.76B	$1.97B
Total assets	$15.5B	$17.1B	$15.7B	$18.2B	$20.0B	$33.5B	$28.3B	$28.3B	$25.8B	$20.1B
Total liabilities	$7.33B	$8.00B	$7.85B	$10.3B	$11.3B	$24.4B	$22.4B	$19.8B	$18.8B	$14.0B
Long-term debt	$2.78B	$3.51B	$3.48B	$4.81B	$5.79B	$17.1B	$15.2B	$11.1B	$10.4B	$9.47B
Shareholders' equity	$8.29B	$9.12B	$7.84B	$7.88B	$8.69B	$9.08B	$5.83B	$8.40B	$6.96B	$6.13B
Cash flow
Operating cash flow	$1.65B	$1.71B	$2.02B	$2.10B	$1.87B	$2.22B	$1.21B	$1.73B	$1.02B	$845.0M
Capital expenditure	$719.0M	$616.0M	$659.0M	$696.0M	$709.0M	$691.0M	$377.0M	$432.0M	$446.0M	$513.0M
Free cash flow	$935.0M	$1.10B	$1.36B	$1.41B	$1.16B	$1.53B	$834.0M	$1.29B	$573.0M	$332.0M
Dividends paid	$268.0M	$315.0M	$376.0M	$423.0M	$473.0M	$530.0M	$573.0M	$586.0M	$590.0M	$348.0M
Share buybacks	$292.0M	$564.0M	$2.45B	$1.27B	$500.0M	$600.0M	$32.0M	$0	$0	—

RevenueNet incomeNet margin (right axis, %)

Baxter International quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$2.70B	$2.75B	$2.63B	$2.81B	$2.83B	$2.97B	$2.70B	$2.96B
Growth (year over year)	+3.8%	+0.9%	+5.4%	+4.3%	+5.0%	+8.0%	+2.9%	+5.3%
Gross profit	$1.03B	$959.0M	$861.0M	$991.0M	$950.0M	$577.0M	$891.0M	$1.03B
Gross margin	38.3%	34.8%	32.8%	35.3%	33.5%	19.4%	33.0%	34.9%
Operating income	$155.0M	−$435.0M	$58.0M	$191.0M	$172.0M	−$729.0M	$66.0M	$217.0M
Operating margin	5.7%	−15.8%	2.2%	6.8%	6.1%	−24.5%	2.4%	7.3%
Net income	$140.0M	−$512.0M	$126.0M	$91.0M	−$46.0M	−$1.13B	−$15.0M	$126.0M
Net margin	5.2%	−18.6%	4.8%	3.2%	−1.6%	−37.9%	−0.6%	4.3%
EPS (diluted)	$0.27	−$1.00	$0.25	$0.18	−$0.09	−$2.21	−$0.03	$0.24
Balance sheet
Cash and equivalents	$1.42B	$1.76B	$2.29B	$1.69B	$1.73B	$1.97B	$2.02B	$2.15B
Total assets	$26.7B	$25.8B	$21.3B	$21.0B	$21.1B	$20.1B	$19.8B	$19.8B
Total liabilities	$18.7B	$18.8B	$14.3B	$13.8B	$13.9B	$14.0B	$13.8B	$13.6B
Long-term debt	$10.4B	$10.4B	—	—	—	$9.47B	—	—
Shareholders' equity	$7.87B	$6.96B	$7.08B	$7.32B	$7.24B	$6.13B	$6.04B	$6.21B
Cash flow
Operating cash flow	$253.0M	$488.0M	−$193.0M	$217.0M	$237.0M	$584.0M	$213.0M	$285.0M
Dividends paid	$148.0M	$147.0M	$87.0M	$87.0M	$87.0M	$87.0M	$5.00M	$5.00M

From Baxter International's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Baxter International vs the Health Care sector and the S&P 500

Baxter International's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Baxter International compared with the median Health Care company and the median S&P 500 company
Measure	Baxter International	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+5.7%	+7.2%	+7.0%
Net margin, latest fiscal year	−8.5%	13.1%	13.0%
Dividend per share, latest fiscal year	$0.52	$2.48	$2.40
Share price change, 1 year	+7.7%	+21.2%	+6.6%

Baxter International: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 21, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Baxter International included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 21, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.